The effects of hippocampal opioidergic and septal GABAergic system interactions on anxiety-like behavior in rats

Ashabi, Ghorbangol; Oryan, Shahrbanoo; Ahmadi, Roya; Valizadegan, Farhad

doi:10.1016/j.lfs.2011.09.009

“…For example, electrolytic lesion of the MS, which decreased AChE activity in the HPC, reduced anxiety of rats during successive alleys tests (innate anxiety) and reduced freezing in contextual conditioned fear (learned fear) ( Bannerman et al, 2004 ). Pharmacological inhibition of the MS (with tetrodotoxin, muscimol, or lidocaine infusion) decreased unconditioned and conditioned anxiety ( Degroot et al, 2001 ; Degroot and Treit, 2004 ; Lamprea et al, 2010 ), whereas pharmacological activation of the MS (with bicuculline) increased innate anxiety in rats ( Ashabi et al, 2011 ). Cholinergic neurons are involved in MS-mediated anxiety/fear.…”

Section: The Medial Septum As a Target For Deep Brain Stimulation For Epilepsy Control And Beyondmentioning

confidence: 99%

The Medial Septum as a Potential Target for Treating Brain Disorders Associated With Oscillopathies

Takeuchi

¹

,

Nagy

²

,

Barcsai

³

et al. 2021

Front. Neural Circuits

View full text Add to dashboard Cite

The medial septum (MS), as part of the basal forebrain, supports many physiological functions, from sensorimotor integration to cognition. With often reciprocal connections with a broad set of peers at all major divisions of the brain, the MS orchestrates oscillatory neuronal activities throughout the brain. These oscillations are critical in generating sensory and emotional salience, locomotion, maintaining mood, supporting innate anxiety, and governing learning and memory. Accumulating evidence points out that the physiological oscillations under septal influence are frequently disrupted or altered in pathological conditions. Therefore, the MS may be a potential target for treating neurological and psychiatric disorders with abnormal oscillations (oscillopathies) to restore healthy patterns or erase undesired ones. Recent studies have revealed that the patterned stimulation of the MS alleviates symptoms of epilepsy. We discuss here that stimulus timing is a critical determinant of treatment efficacy on multiple time scales. On-demand stimulation may dramatically reduce side effects by not interfering with normal physiological functions. A precise pattern-matched stimulation through adaptive timing governed by the ongoing oscillations is essential to effectively terminate pathological oscillations. The time-targeted strategy for the MS stimulation may provide an effective way of treating multiple disorders including Alzheimer’s disease, anxiety/fear, schizophrenia, and depression, as well as pain.

show abstract

“…Particularly, naloxone has been proved to active the mu receptor, which in turn interact with dopaminergic and acetylcholine system facilitating neurotransmitter releasing to alleviate cognitive and psychotic symptom ( 9 , 10 , 22 ). This phenomenon suggests a causal relationship with the gamma-aminobutyric acid (GABA)ergic system ( 23 , 24 ). Agitation in delirium is very complex that needs to be addressed.…”

Section: Discussionmentioning

confidence: 99%

Naloxone Alleviate the Severity of Delirium in Hospitalized Patients With Parkinsonism: Three Case Reports

Jin

¹

,

Zhang

²

,

Hu

³

et al. 2021

Front. Psychiatry

2

0

View full text Add to dashboard Cite

Purpose: Delirium is common in geriatric with Parkinson's disease (PD). Treatments for delirium have generally been neuroleptics; however, antipsychotics have potential effect to block striatal dopamine D2 receptors and worsen symptom of parkinsonism. We explored whether naloxone can alleviate delirium in PD and other forms of parkinsonism.Patients and Methods: Patients with parkinsonism who met the delirium criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) received naloxone infusions once or twice daily. Treatment effects were evaluated by the delirium rating scale–revised 98 (DRS-R98), including non-cognitive and cognitive subscales; the Richmond agitation–sedation scale (RASS); and the mini mental status examination (MMSE).Results: Two patients with primary parkinsonism, one with vascular PD were observed. The daily dose of naloxone was 2.08 ± 0.64 mg (range: 1–4 mg). Medication time last from 1 h to 7 days without side effects observed. Following with naloxone infusions, DRS-R98 scores decreased within 12 h and MMSE scores increased. The psychotic symptoms, disorientation, and attention deficits were alleviated significantly, while RASS scores decreased with naloxone treatment.Conclusion: Naloxone alleviated psychotic symptoms, improved cognitive dysfunction, and irritability in patients with delirium in the context of PD. The preliminary findings point out that the opioid system may be involved in the pathophysiology of delirium, which may be one of potential treat targets for delirium of PD.

show abstract

“…For example, electrolytic lesion of the MS, which decreased AChE activity in the HPC, reduced anxiety of rats during successive alleys tests (innate anxiety) and reduced freezing in contextual conditioned fear (learned anxiety/fear) (Bannerman et al, 2004). Pharmacological inhibition of the MS (with tetrodotoxin, muscimol, or lidocaine infusion) decreased unconditioned and conditioned anxiety (Degroot et al, 2001;Degroot and Treit, 2004;Lamprea et al, 2010), whereas pharmacological activation of the MS (with bicuculline) increased anxiety in rats (Ashabi et al, 2011). Cholinergic neurons are involved in MS-mediated anxiety/fear.…”

Section: Anxiety/fearmentioning

confidence: 99%

The Medial Septum as a Potential Target for Treating Brain Disorders Associated with Oscillopathies

Takeuchi

¹

,

Nagy

²

,

Barcsai

³

et al. 2021

Preprint

View full text Add to dashboard Cite

The medial septum (MS), as part of the basal forebrain, supports many physiological functions, from sensorimotor integration to cognition. With often reciprocal connections with a broad set of peers at all major divisions of the brain, the MS orchestrates oscillatory neuronal activities throughout the brain. These oscillations are critical in generating sensory and emotional salience, locomotion, maintaining mood, supporting innate anxiety, and governing learning and memory. Accumulating evidence points out that the physiological oscillations under septal influence are frequently disrupted or altered in pathological conditions. Therefore, the MS may be a potential target for treating neurological and psychiatric disorders with abnormal oscillations (oscillopathies) to restore healthy patterns or erase undesired ones. Recent studies have revealed that the patterned stimulation of the MS alleviates symptoms of epilepsy. We discuss here that stimulus timing is a critical determinant of treatment efficacy on multiple time scales. On-demand stimulation may dramatically reduce side effects by not interfering with normal physiological functions. A precise pattern-matched stimulation through adaptive timing governed by the ongoing oscillations is essential to effectively terminate pathological oscillations. The time-targeted strategy for the MS stimulation may provide an effective way of treating multiple disorders including Alzheimer’s disease, anxiety/fear, schizophrenia, and depression, as well as pain.

show abstract

The effects of hippocampal opioidergic and septal GABAergic system interactions on anxiety-like behavior in rats

Cited by 11 publications

References 48 publications

The Medial Septum as a Potential Target for Treating Brain Disorders Associated With Oscillopathies

The Medial Septum as a Potential Target for Treating Brain Disorders Associated With Oscillopathies

Naloxone Alleviate the Severity of Delirium in Hospitalized Patients With Parkinsonism: Three Case Reports

The Medial Septum as a Potential Target for Treating Brain Disorders Associated with Oscillopathies

Contact Info

Product

Resources

About